Navigation Links
GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
Date:11/18/2011

SAN DIEGO, Nov. 18, 2011 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, Inc., today announced study results and the commercial launch of PREvent™. FirstMark PREvent is the first multiple biomarker test that accurately predicts near term (approximately 2-3 years) risk of myocardial infarction (MI) for suspected or confirmed coronary artery disease (CAD) patients. FirstMark PREvent was launched, and the data from the phase I prospective study entitled, "Aggregate Risk Score Based on Markers of Inflammation, Immunity, and Thrombosis is an Independent Predictor of Adverse Cardiovascular Outcomes," was presented by Danny J. Eapen, MD, at the American Heart Association Scientific Sessions 2011 (AHA), in Orlando, Florida.

PREvent is a simple blood test based on technology developed and patented by GenWay, Emory University and MedStar. The test aggregates three biomarkers that identify the multiple pathways that lead to vulnerable plaques. The development and validation studies for the test were comprised of approximately 3,000 individuals with suspected or confirmed CAD. The studies showed PREvent to be significantly more powerful than other tests and risk factors, by identifying the top 10% of confirmed CAD patients that are at a 6.45 times higher risk of a near term MI within a 2-3 year period, as compared to other CAD patients. The test also proved to be 12 times more powerful than the single biomarker CRP. In addition, 18% of CAD patients with all three biomarkers elevated had a major event within the first year, compared to only 2% of CAD patients with normal biomarker levels.

PREvent is a critical advancement in cardiovascular medicine addressing the unmet need to access risk of near term MI. "This simple blood test is an exciting development for suspected or confirmed CAD patients, allowing physician's diagnostic clarity in identifying CAD patients that are in most urgent need of aggressive treatment and monitoring," said Thomas Silberg, President and CEO of GenWay Biotech. FirstMark PREvent is now available and will be targeted to primary care physicians and cardiologists.

The AHA Scientific Sessions 2011 abstract and additional information about the test is available at http://www.FirstMarkPREvent.com

About GenWay Biotech, Inc.
GenWay Biotech, is comprised of three divisions. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. GenWay's catalog products and custom services divisions are focused on protein and antibody solutions. GenWay's headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area.

Media Contact: Deborah Moore GenWay Biotech, Inc., 858-458-0855, dmoore@genwaybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE GenWay Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Acquires Seppro(R) Depletion Technology From GenWay Biotech
2. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
3. Yongye Biotechnology International Retains CCG Investor Relations
4. ThirdBiotech Announces Kemeta as Newest Sponsor
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
7. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
8. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
9. China Kangtai Cactus Biotech Announces Record Second Quarter Results
10. Yongye Biotechnology International Announces Second Quarter Results
11. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):